Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies

被引：0

作者：

Xingsheng Hu

Shucai Zhang

Zhiyong Ma

Jifeng Feng

Lin Wu

Dongqing Lv

Jianying Zhou

Xiaodong Zhang

Li Liu

Qitao Yu

Wangjun Liao

Yiping Zhang

Xiang Wang

Ying Cheng

Hongrui Niu

Ziping Wang

Dong Wang

Cheng Huang

Chunling Liu

Hui Zhao

Jian Feng

Jingzhang Li

Kejing Ying

Nong Yang

Shukui Qin

Jie Hu

Fei Liu

Yong Jiang

Nan Ge

Yuankai Shi

机构：

[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[2] Chinese Academy of Medical Sciences & Peking Union Medical College,Department of Oncology

[3] Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs,Department of Medical Oncology

[4] Beijing Chest Hospital,Department of Oncology

[5] Capital Medical University,Thoracic Medicine Department II, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine

[6] Beijing Tuberculosis and Thoracic Oncology Institute,Department of Respiratory Medicine

[7] Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital,Department of Respiratory Medicine

[8] Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research,Department of Medical Oncology

[9] Nanjing Medical University Affiliated Cancer Hospital,Department of Thoracic Oncology, Cancer Center

[10] Central South University,Department of Respiratory Oncology

[11] Taizhou Hospital of Zhejiang Province,Department of Oncology

[12] The First Affiliated Hospital,Department of Medical Oncology

[13] Zhejiang University School of Medicine,Department of Medical Oncology

[14] Nantong Cancer Hospital,Department of Oncology

[15] Union Hospital,Department of Oncology

[16] Tongji Medical College,Department of Thoracic Medical Oncology

[17] Huazhong University of Science and Technology,Department of Oncology

[18] Guangxi Medical University Affiliated Tumor Hospital,Department of Oncology

[19] Nanfang Hospital,Department of Pulmonary Medicine

[20] Southern Medical University,Department of Respiratory and Critical Care Medicine

[21] Zhejiang Cancer Hospital,Department of Respiratory Medicine

[22] Xuzhou Central Hospital,Department of Oncology

[23] Jilin Cancer Hospital,Department of Respiratory Medicine

[24] The First Affiliated Hospital of Xinxiang Medical University,Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit

[25] Peking University Cancer Hospital and Institute,The People’s Liberation Army Cancer Center

[26] Army Medical Centre of People’s Liberation Army,undefined

[27] Fujian Cancer Hospital,undefined

[28] Cancer Hospital of Xinjiang Medical University,undefined

[29] The Second Hospital of Anhui University,undefined

[30] Affiliated Hospital of Nantong University,undefined

[31] Liuzhou People’s Hospital,undefined

[32] Sir Run Shaw Hospital,undefined

[33] Zhejiang University School of Medicine,undefined

[34] Zhejiang University,undefined

[35] Hunan Cancer Hospital,undefined

[36] the Affiliated Cancer Hospital of Xiangya School of Medicine,undefined

[37] Central South University,undefined

[38] Jinling Hospital,undefined

[39] Shanghai Allist Pharmaceutical Technology Co.,undefined

[40] Ltd,undefined

来源：

BMC Medicine | / 21卷

关键词：

NSCLC; Furmonertinib; AST2818; CNS;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 174 条

[1]

Shi Y(2014)A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncol 9 154-162

[2]

Au JS(2015)Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study PloS one. 10 e0143515-2388

[3]

Thongprasert S(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-742

[4]

Srinivasan S(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-2450

[5]

Tsai CM(2017)First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study Ann Oncol 28 2443-222

[6]

Khoa MT(2014)Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 15 213-1466

[7]

Shi Y(2017)Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Lancet Oncol 18 1454-1415

[8]

Li J(2013)Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC Cancer Discov 3 1404-1061

[9]

Zhang S(2014)AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 1046-1699

[10]

Wang M(2015)AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N Engl J Med 372 1689-640

← 1 2 3 4 5 6 7 8 9 10 →